Clinical Trial Update: A Study of Sargramostim Plus Pembrolizumab with or Without Pemetrexed in Patients with Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating sargramostim plus pembrolizumab with or without pemetrexed in advanced non-small cell lung cancer after chemoimmunotherapy has been t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Pemetrexed (pemetrexed)
• sargramostim (sargramostim)

Snippet

Sponsor: Tufts Medical Center | Conditions: Advanced Lung Non-Small Cell Carcinoma, Non-Small Cell Carcinoma of Lung, TNM Stage 4 | Phase 2 | Status: TERMINATED